TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12414848
Drug: Intermittent treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent treatment with 0.8 mg GH/d for 14 days every 3 months (group B)
Study: 28188086
Drug: Both treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatment groups (A and B)
Study: 8681976
Drug: Once-daily dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily dosing of aminoglycosides
Study: 1695801
Drug: Chemotherapy group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy group (89 patients) received Vincristine (1.5 mg/m2), Bleomycin (15 mg), Methotrexate (80 mg)
Study: 1695801
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (chemotherapy and control)
Study: 356761
Drug: Intermittent levamisole
Normalized name: Levamisole
DrugBank: Levamisole (DB00848)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intermittent levamisole therapy (150 mg daily for 3 days of each week)
Study: 356761
Drug: Continuous levamisole
Normalized name: Levamisole
DrugBank: Levamisole (DB00848)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuous levamisole therapy (150 mg daily)
Study: 3585450
Drug: Immediate-release morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release morphine sulfate (IRMS)
Study: 16342193
Drug: Collection of
Normalized name: Reveos Select CPD with AS-5 Red Cell Preservative Solution For Collection Of 500ml Of Blood KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Collection of peripheral blood progenitor cells (PBPCs) on day 5 after G‐CSF administration.
Study: 16342193
Drug: G‐CSF mobilization
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐CSF mobilization of CD34(+) cells.
Study: 10542895
Drug: 500 ml
Normalized name: TPN Bag 500 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 ml 10% HES 200/0.5
Study: 2312773
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg metoprolol CR/ZOK
Study: 7010383
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg cefaclor 3‐times daily (intermittent)
Study: 7010383
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg amoxycillin 3‐times daily (continuous)
Study: 30896743
Drug: Calcium intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium intake (mean 886 mg/day)
Study: 15494457
Drug: GnRH (gonadotropin-releasing
Approvals — FDA: no, EMA: no, PMDA: no
Description: GnRH (gonadotropin-releasing hormone) bolus iv injection
Study: 10455843
Drug: Buscopan 20
Normalized name: Buscopan 20 MG/ML Injectable Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buscopan 20 mg
Study: 2193555
Drug: 1-methadone (1.145
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-methadone (1.145 mg)
Study: 2193555
Drug: 1-methadone (0.573
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-methadone (0.573 mg) + metamizol (50 mg)
Study: 19683731
Drug: Oral oxybutynin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral oxybutynin
Study: 19827464
Drug: 6.4% maltodextrin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6.4% maltodextrin solution (CHO)
Study: 2053765
Drug: 360 mg
Normalized name: aspirin 360 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 360 mg sustained release verapamil as two divided doses
Study: 6352209
Drug: Pulsed intermittent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsed intermittent subcutaneous insulin infusion (30‐, 60‐, and 120‐min intervals)
Study: 30080693
Drug: Instillation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Instillation of prophylactic antibiotic drops (AB) each morning/evening
Study: 30080693
Drug: Daily lens
Normalized name: lens scale pollen extract
DrugBank: Atriplex lentiformis pollen (DB10760)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily lens cleaning (LC) each morning
Study: 29072017
Drug: Western medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medicine (intravenous injection of aspartate ornithine and branched chain amino acids)
Study: 9537455
Drug: 15 microg
Normalized name: Tafluprost 15 microgram/mL eye drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 microg of consensus interferon administered subcutaneously three times a week for 24 weeks
Study: 9537455
Drug: 15 microg
Normalized name: Tafluprost 15 microgram/mL eye drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 microg of consensus interferon administered subcutaneously three times a week for 48 weeks
Study: 7819467
Drug: Atropine 2
Normalized name: atropine 2 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine 2 micrograms/kg administered in 60 sec. intervals up to a total dose of 10 micrograms/kg
Study: 2458264
Drug: Infusion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of trypsin (150 mg h‐1; 1.25 g l‐1)
Study: 2458264
Drug: Infusion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of aprotinin (1.5 X 10(6) KIU for 30 min)
Study: 2458264
Drug: Infusion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of trypsin (300 mg h‐1; 2.5 g l‐1)
Study: 21389180
Drug: High-protein and
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-protein and moderate-carbohydrate diet (HPMC; 139 g protein, 82 g fat, 181 g carbohydrate/d)
Study: 21389180
Drug: High-protein and
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-protein and low-carbohydrate diet (HPLC; 137 g protein, 143 g fat, 22 g carbohydrate/d)
Study: 21389180
Drug: Weight-maintenance diet
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weight-maintenance diet (85 g protein, 116 g fat, 360 g carbohydrate/d)
Study: 11849198
Drug: SJW (0.15%)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SJW (0.15%) 600 mg three times daily for 16 days
Study: 2185350
Drug: Treatment of
Normalized name: DRUGS FOR TREATMENT OF LEPRA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment of risk factors (specific interventions not detailed)
Study: 463804
Drug: Corn syrup
Normalized name: Corn Syrup
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corn syrup diets (45% of total energy)
Study: 463804
Drug: Corn syrup
Normalized name: Corn Syrup
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corn syrup diets (65% of total energy)
Study: 23352229
Drug: Intranasal oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal oxytocin (16IU)
Study: 2879389
Drug: Celiprolol (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celiprolol (300 mg for 4 weeks)
Study: 2879389
Drug: Metoprolol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (200 mg for 4 weeks)
Study: 25319061
Drug: Abituzumab 500
Normalized name: sacituzumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abituzumab 500 mg combined with cetuximab and irinotecan (arm A)
Study: 25319061
Drug: Abituzumab 1000
Normalized name: obinutuzumab
DrugBank: Obinutuzumab (DB08935)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Abituzumab 1000 mg combined with cetuximab and irinotecan (arm B)
Study: 21889560
Drug: Switching group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Switching group (paroxetine 20-40 mg)
Study: 17444378
Drug: Polarised light
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polarised light treatment (once daily for 10 minutes on sacral area and both heels)
Study: 8506453
Drug: Gammahydroxybutyrate (GHB),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gammahydroxybutyrate (GHB), 60 mg/kg/night
Study: 3829910
Drug: Ascot preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ascot preparation of procainamide hydrochloride
Study: 3829910
Drug: Squibb preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Squibb preparation of procainamide hydrochloride
Study: 2575983
Drug: epanolol 200mg
Normalized name: epanolol
DrugBank: Epanolol (DB13757)
Approvals — FDA: no, EMA: no, PMDA: no
Description: epanolol 200mg once daily
Study: 2575982
Drug: metoprolol 100mg
Normalized name: HCTZ 25/METOPROLOL 100MG TAB
DrugBank: Metoprolol (DB00264)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: metoprolol 100mg twice daily
Study: 28390289
Drug: Lenvatinib 24
Normalized name: lenvatinib 24 MG Daily Dose 30 Day Supply Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenvatinib 24 mg orally once daily
Study: 23735418
Drug: Low intracellular
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low intracellular magnesium (iMg) levels (<3.75 mg/dL erythrocytes)
Study: 21255610
Drug: NIM811 monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NIM811 monotherapy (doses of 10 to 600 mg orally once or twice daily)
Study: 21255610
Drug: NIM811 (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: NIM811 (600 mg bid) in combination with pegylated interferon alpha (PEG‐IFN‐α)
Study: 10961521
Drug: CHO-electrolyte solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHO-electrolyte solution (CE)
Study: 2868736
Drug: Thiopental loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiopental loading added to standard therapy
Study: 27224908
Drug: Tapentadol ER
Normalized name: tapentadol Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tapentadol ER (25-250 mg)
Study: 20197167
Drug: Over-the-counter analgesics
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Over-the-counter analgesics (OTC)
Study: 18550582
Drug: Daily free
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily free distribution program
Study: 9682041
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg of alendronate per day
Study: 9682041
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of alendronate per day
Study: 17190893
Drug: Alendronate (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate (both doses)
Study: 7897120
Drug: No thrombolytic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No thrombolytic therapy (baseline ECG)
Study: 2482549
Drug: Placebo (subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (subcutaneous injections)
Study: 21988334
Drug: Tolvaptan 30
Normalized name: tolvaptan 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolvaptan 30 mg with ketoconazole 200 mg once daily for 3 days
Study: 21988334
Drug: Tolvaptan 240
Normalized name: Tolvaptan
DrugBank: Tolvaptan (DB06212)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tolvaptan 240 mg with rifampicin 600 mg once daily for 7 days
Study: 29484495
Drug: Rotigotine transdermal
Normalized name: Rotigotine Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rotigotine transdermal patch
Study: 17935234
Drug: Rotigotine transdermal
Normalized name: Rotigotine Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rotigotine transdermal patch (doses ≤8 mg/24 h)
Study: 12483368
Drug: Amifostine (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amifostine (500 mg on each day of chemotherapy)
Study: 9616310
Drug: Antituberculous chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antituberculous chemotherapy
Study: 9616310
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no antituberculous chemotherapy)
Study: 2613389
Drug: Solid paracetamol
Normalized name: Corydalis solida whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solid paracetamol dosage form (tablets) with meal enriched in dietary fiber
Study: 2613389
Drug: Liquid and
Normalized name: KIT, LIQUID AND TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid and solid paracetamol dosage forms
Study: 870376
Drug: oral mannitol
Normalized name: Mannitol
DrugBank: Mannitol (DB00742)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral mannitol to induce diarrhea
Study: 30694697
Drug: Dasotraline 4
Normalized name: Dasotraline
DrugBank: Dasotraline (DB12305)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dasotraline 4 mg/day
Study: 21324520
Drug: Daily beclomethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily beclomethasone (twice daily, 40 μg per puff)
Study: 21324520
Drug: Combined (twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined (twice daily beclomethasone with beclomethasone plus albuterol as rescue)
Study: 21324520
Drug: Rescue beclomethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rescue beclomethasone (twice daily placebo with beclomethasone plus albuterol as rescue)
Study: 17580440
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment (Quchi, Lieque, Yuji, Neiguan, Zusanli, Sanyinjiao, Taixi) once daily for 12 days
Study: 17580440
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group treated with anti-asthma drugs (Cromolyn sodium, Albuterol, fenoterol)
Study: 17580440
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment for moderate and severe asthma
Study: 17580440
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group treated with anti-asthma drugs
Study: 12575376
Drug: Xuejie Jiawei
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xuejie Jiawei Decoction No. II, one dose per day for 5 days, starting from the 11th day after abortion
Study: 9622044
Drug: Clonidine plus
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clonidine plus neuroleptic (dosage of clonidine varied from 0.2 to 0.6 mg per day, neuroleptic averaged 34 mg per day of haloperidol equivalents)
Study: 9622044
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus neuroleptic (neuroleptic averaged 34 mg per day of haloperidol equivalents)
Study: 1769029
Drug: Continuous patch
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous patch application (Group A)
Study: 1769029
Drug: First dose
Normalized name: Cow first milk
DrugBank: Bos taurus colostrum (DB19249)
Approvals — FDA: no, EMA: no, PMDA: no
Description: First dose of the nitroglycerin patch
Study: 28093604
Drug: 5% 5-fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% 5-fluorouracil (5-FU) pretreatment for 7 days, twice daily before daylight-mediated photodynamic therapy (PDT)
Study: 28093604
Drug: Daylight-mediated photodynamic
Normalized name: carbinoxamine maleate Oral Solution [Pediatex]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daylight-mediated photodynamic therapy (PDT) alone
Study: 22392326
Drug: Rolls fortified
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rolls fortified with microencapsulated iron sulfate (4 mg iron each), offered once a day, five days a week for 24 weeks.
Study: 20662314
Drug: Rosiglitazone maleate
Normalized name: Rosiglitazone Maleate
DrugBank: Rosiglitazone (DB00412)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rosiglitazone maleate sustained-release floating microspheres
Study: 20662314
Drug: Commercial tablets
Normalized name: iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Commercial tablets (control)
Study: 18363603
Drug: Erythropoiesis stimulating
Normalized name: Erythropoiesis stimulating agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythropoiesis stimulating agents (ESA)
Study: 1549650
Drug: l-fenfluramine (l-FF)
Normalized name: fenfluramine
DrugBank: Fenfluramine (DB00574)
Approvals — FDA: no, EMA: no, PMDA: no
Description: l-fenfluramine (l-FF) + d-amphetamine (d-amp)
Study: 1549650
Drug: l-fenfluramine (l-FF)
Normalized name: fenfluramine
DrugBank: Fenfluramine (DB00574)
Approvals — FDA: no, EMA: no, PMDA: no
Description: l-fenfluramine (l-FF)
Study: 27575854
Drug: KLOX BioPhotonic
Normalized name: Kloxxado
DrugBank: Naloxone (DB01183)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: KLOX BioPhotonic System (LED blue light device with photo-converter chromophores), treated for 6 weeks (twice weekly)
Study: 22459647
Drug: No additional
Approvals — FDA: no, EMA: no, PMDA: no
Description: No additional treatment (group A)
Study: 6089304
Drug: Ranitidine 150
Normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ranitidine 150 mg twice daily for 4 weeks
Study: 6119777
Drug: Ranitidine after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine after initial treatment
Study: 6119777
Drug: Ranitidine after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine after initial placebo treatment
Study: 31358470
Drug: 4-week walking
Normalized name: milnacipran
DrugBank: Milnacipran (DB04896)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4-week walking intervention aimed at increasing daily steps
Study: 23516092
Drug: Gushen Pian
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gushen Pian (double-blind treatment group)
Study: 11528230
Drug: Blood flow
Normalized name: NITRIC OXIDE 400 mg in 500 mg TOPICAL CAPSULE [Bio NO Brain Care (Helps improve Brain blood flow and body temperature, Fermented Garlic powder)]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood flow rate (Qb) 300 ml/min
Study: 11528230
Drug: Blood flow
Normalized name: NITRIC OXIDE 400 mg in 500 mg TOPICAL CAPSULE [Bio NO Brain Care (Helps improve Brain blood flow and body temperature, Fermented Garlic powder)]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood flow rate (Qb) 200 ml/min
Study: 11528230
Drug: Blood flow
Normalized name: NITRIC OXIDE 400 mg in 500 mg TOPICAL CAPSULE [Bio NO Brain Care (Helps improve Brain blood flow and body temperature, Fermented Garlic powder)]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood flow rate (Qb) 400 ml/min
Study: 9935259
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg trovafloxacin by mouth
Study: 9935259
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g cefoxitin by i.v. infusion
Study: 29565660
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care plus Oral Health 4 Life (OH4L)
Study: 28991280
Drug: Platelet-rich plasma
Normalized name: PLATELET-RICH PLASMA, AUTOLOGOUS
DrugBank: Platelet Rich Plasma (DB19295)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platelet-rich plasma (PRP) administration during internal fracture reduction
Study: 12852707
Drug: Fluvastatin ER
Normalized name: fluvastatin Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin ER 80 mg QD
Study: 12852707
Drug: Fluvastatin IR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin IR 40 mg QD
Study: 10665628
Drug: Citalopram 10
Normalized name: citalopram 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram 10 mg/day
Study: 25500685
Drug: Citalopram 40
Normalized name: citalopram 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram 40 mg/day
Study: 8604406
Drug: Treatment of
Normalized name: DRUGS FOR TREATMENT OF LEPRA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment of catheter-related infection
Study: 8604406
Drug: 4 to
Normalized name: LMX 4 Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 to 6 weeks of therapy for infection in men
Study: 15500134
Drug: RAS blockers
Normalized name: RAS
DrugBank: Rasagiline (DB01367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: RAS blockers
Study: 28095795
Drug: Intrathecal magnesium
Normalized name: beractant
DrugBank: Beractant (DB06761)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrathecal magnesium sulfate (50 mg)
Study: 8384733
Drug: Subcutaneous vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous vaccine
Study: 19728561
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation of fexofenadine
Study: 19728561
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation of fexofenadine
Study: 11563193
Drug: Dan Shao
Normalized name: Dan shen suan b
DrugBank: Salvianolic acid B (DB19313)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dan Shao Tang and western medicine
Study: 9876347
Drug: hGH treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: hGH treatment
Study: 8039024
Drug: Topical lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical lidocaine (anaesthesia of the nose)
Study: 2930092
Drug: Caffeine (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (250 mg of caffeine sodium benzoate)
Study: 17471830
Drug: Pulsed electromagnetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsed electromagnetic fields (PEMF) therapy
Study: 11797269
Drug: Chemotherapy (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (standard treatment)
Study: 11797269
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of epirubicin-cisplatin-continuous 5FU (ECF)
Study: 11797269
Drug: Radio-chemotherapy
Normalized name: Valerianae radix
DrugBank: Valerian (DB13196)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radio-chemotherapy
Study: 11797269
Drug: 5FU alone,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5FU alone, 5FU-cisplatin, or 5FU-mitomycin (as preoperative or exclusive treatment)
Study: 7817618
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg bisoprolol once daily
Study: 21035560
Drug: Salmeterol 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol 200 μg
Study: 30836363
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg lycopene, 5.8 mg phytoene and phytofluene, 0.8 mg β-carotene, 5.6 mg tocopherols from tomato extract, and 4 mg carnosic acid from rosemary extract per day
Study: 30993855
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine 100 units/mL (Gla-100)
Study: 9432453
Drug: Immediate treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate treatment group
Study: 9848758
Drug: Endotracheal continuous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endotracheal continuous positive airway pressure (ETCPAP) after rescue surfactant therapy
Study: 7815711
Drug: Pipecuronium bromide
Normalized name: pipecuronium bromide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pipecuronium bromide 0.04 mg.kg‐1
Study: 7815711
Drug: Vecuronium bromide
Normalized name: Vecuronium Bromide
DrugBank: Vecuronium (DB01339)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vecuronium bromide 0.08 mg.kg‐1